by Maria Zannes | Jul 13, 2016 | Press Releases
JULY 13, 2016 (SAN ANTONIO, TX) bioAffinity Technologies today announced the renewal of its collaborative agreement with The University of Texas Health Science Center at San Antonio for research and development of novel cancer diagnostic and therapeutic agents using...
by Maria Zannes | Jul 7, 2016 | Press Releases
JULY 7, 2016 (SAN ANTONIO, TX) bioAffinity Technologies today announced that William Bauta, Ph.D., will join the company in September 2016 as Senior Vice President for Research and Development, Therapeutics. Dr. Bauta will direct the development and commercialization...
by Maria Zannes | Jun 23, 2016 | Press Releases
JUNE 23, 2016 (SAN ANTONIO, TX ) bioAffinity Technologies today announced the formation of OncoSelect Therapeutics, LLC, a subsidiary company that will leverage bioAffinity’s proprietary porphyrin-based diagnostic technology to target a variety of cancers for...
by Maria Zannes | Apr 4, 2016 | Press Releases
APRIL 4, 2016 (SAN ANTONIO, TX) bioAffinity Technologies, a privately held cancer diagnostics company, today announced that Vivienne Rebel, M.D., Ph.D., has joined the Company as Executive Vice President of Research and Development (R&D) and Chief Medical and...
by Maria Zannes | Dec 14, 2015 | Press Releases
DECEMBER 14, 2015 (SAN ANTONIO, TX ) bioAffinity Technologies announced the People’s Republic of China awarded a Certificate of Invention Patent for the Company’s proprietary CyPath® assay, a bio-label that preferentially binds to cancer cells and labels them a...
by Maria Zannes | Dec 10, 2015 | Press Releases
DECEMBER 10, 2015 SAN ANTONIO–(BUSINESS WIRE)–The porphyrin compound used in bioAffinity Technologies’ proprietary CyPath® Lung is a novel marker for endocytosis, new research shows. Endocytosis is a process that is often disrupted in cancer. The finding will be...
